As at June 30, 2008 the Company had 55,883,437 common shares and 6,483,738 stock options outstanding.
Management's Discussion and Analysis of the financial statements for the three-month and six-month periods ended June 30, 2008 is available on SEDAR at http://www.sedar.com.
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based test that can assess an individual's current risk for colorectal cancer. For more information on GeneNews, visit http://www.genenews.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein. Investors should
consult the Company's ongoing quarterly filings and annual reports for
additional information on risks and uncertainties relating to these
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
CONSOLIDATED BALANCE SHEETS
(Expressed in Canadian dollars)
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved